DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. SICOR PHARMACEUTICALS, INC.
|Date Filed||Document No.||Description||Snippet||Link To Document|
|2007-04-27||125||1 The patents at issue are U.S. Patent Nos. 4,808,614 and 5,464,826. Compl. ¶¶ 11…gemcitabine would not infringe upon Lilly’s patents and that said patents are invalid. Defs.’ Mem. at 5-6. …ANDAs, and therefore also infringed upon Lilly’s patents.2 On May 12, 2006, Defendants filed this…time frame after being notified of the potential patent infringement. The California …Circuit law governs personal jurisdiction issues in patent infringement cases. See Hildebrand v. Steck||External link to document|
|2010-03-31||375||4,808,614 (“the ’614 patent”) and 5,464,826 (“the ’826 patent”). The ’614 patent covers the compound … of the ’614 patent: Watamane (1979 (PTX-587); U.S. Patent No. 4,211,733 (“’773 patent”); the Bergstrom…the original patent application ultimately leading to the ’826 patent, the second patent-in-suit. Specifically… ’614 patent and the ’826 patent are invalid for obviousness. Under the United States Patent Act, …infringement of two patents held by Plaintiff Eli Lilly and Company (“Lilly”): United States Patent Nos. 4,808,614||External link to document|
|>Date Filed||>Document No.||>Description||>Snippet||>Link To Document|